Can adding surgery or radiation to immunotherapy boost survival in advanced lung cancer?

NCT ID NCT03391869

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not had immunotherapy before will be randomly assigned to one of two groups. The goal is to see if the combined approach improves overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG ADENOCARCINOMA LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States
MD Anderson League City

League City, Texas, 77573, United States
MD Anderson West Houston

Houston, Texas, 77079, United States
MD Anderson in Sugar Land

Sugar Land, Texas, 77478, United States
MD Anderson in The Woodlands

Conroe, Texas, 77384, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.